Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 21 or older who have given written consent to take part (or whose legal representative has done so on their behalf)
• People who have been diagnosed with a specific type of nose and throat cancer called non-keratinizing nasopharyngeal carcinoma (NPC), confirmed through a tissue or cell test
• People whose cancer can be measured on scans, based on standard medical measurement guidelines
• People whose cancer is at stage III (but not the specific sub-stages T3N0 or T3N1) or stage IVA, as classified by the AJCC 8th edition staging system
• People whose cancer has tested positive for a virus called Epstein-Barr virus (EBV), using a specific lab test called EBER ISH — previous test results may be accepted without re-testing
• People who have not received any prior treatment for this cancer
• People willing to provide blood samples for research studies connected to the trial
• People with a general health and activity level rated as 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work)
• People whose liver, kidneys, and other organs are functioning at an adequate level
• Women who are not pregnant and not breastfeeding, and who either cannot become pregnant or agree to use reliable contraception during treatment and for at least 120 days after the last dose
• Men who agree to use contraception during treatment and for at least 120 days after the last dose, and who agree not to donate sperm during this period

Who may not be able to join:

• People with stage III NPC classified specifically as T3N0 or T3N1 under the AJCC 8th edition
• People who have previously received any cancer treatment, including chemotherapy, radiation, immunotherapy, or experimental treatments
• People who have taken part in another clinical trial or used an experimental medical device within the 4 weeks before the first dose
• People who need ongoing high-dose steroid medication (above 10 mg of prednisone per day) or other immune-suppressing medicines within 14 days before the first dose (some low-dose or localised steroid use may be permitted — confirm with trial site)
• People who have an active autoimmune disease that has needed systemic medical treatment in the past 2 years (hormone replacement therapies such as thyroid or insulin are not counted as systemic treatment)
• People who have had lung inflammation (pneumonitis) in the past that required steroid treatment, or who currently have pneumonitis
• People with a known allergy or sensitivity to bevacizumab or any of its ingredients
• People who have, or have had in the past 3 years, another cancer that is still active or has needed treatment — though certain skin cancers or early-stage cancers that have been successfully treated may still be eligible (confirm with trial site)
• People with an active infection needing treatment, or a serious wound, ulcer, or bone fracture that has not healed
• People with uncontrolled high blood pressure, even while taking three or more blood pressure medications
• People with significant heart conditions, including moderate-to-severe heart failure, unstable or recently developed chest pain, or a heart attack within the past 6 months; or certain heart rhythm problems requiring specific medications
• People with a high level of protein in their urine, above a certain threshold on standard medical grading
• People who have had significant bleeding within the 30 days before starting the trial
• People with a mental health condition or substance use disorder that the treating doctor believes would make it difficult to follow the trial requirements
• People who are pregnant, breastfeeding, or planning to conceive or father a child during the trial period and up to 120 days after the last dose
• Women of childbearing potential who have a positive pregnancy test within 72 hours before being enrolled
• People with a known history of HIV infection (note: HIV testing is not required unless local health authorities require it)
• People with a known history of active Hepatitis B or Hepatitis C infection (note: testing is not required unless local health authorities require it)
• People who have received a live vaccine (such as measles, chickenpox, yellow fever, or BCG) within 30 days before the first dose — most standard flu injections are allowed, but nasal spray flu vaccines are not

**Important: Always verify eligibility with the trial site directly before applying